Please Wait.....
Report
Europe Halal Pharmaceuticals Market Forecast 2025-2032
Market Reprt I 2025-02-01 I 157 Pages I Inkwood Research
KEY FINDINGS
The Europe halal pharmaceuticals market is estimated to rise with a CAGR of 9.47% over the forecast years of 2025 to 2032. The base year regarded for the studied market is 2024, and the forecasting years are from 2025 to 2032.
MARKET INSIGHTS
The European halal pharmaceuticals market is gaining momentum, driven by the growing Muslim population and increasing awareness about ethical and religious compliance in healthcare. Countries like France, the United Kingdom, and Germany dominate the market due to their large Muslim demographics and strong distribution networks.
These countries also benefit from greater acceptance of halal-certified pharmaceuticals. France leads with its well-established halal infrastructure and proactive community engagement, while the UK benefits from strong advocacy groups promoting halal compliance across the healthcare sector.
A notable trend is the rising focus on transparency in sourcing and manufacturing processes, with consumers demanding more than just basic halal certification. Innovative advancements, such as halal pharmaceutical products, including vaccines and biologics, are emerging as breakthroughs.
Market players can seize opportunities by collaborating with European regulatory bodies to streamline halal certification processes. Additionally, educating healthcare providers about halal certified pharmaceuticals can drive adoption, particularly in multicultural regions, ensuring a stronger foothold in this expanding market.
REGIONAL ANALYSIS
The Europe halal pharmaceutical industry growth assessment comprises the evaluation of the United Kingdom, Germany, France, Spain, Italy, Belgium, the Netherlands, and Rest of Europe.
Organizations like the Halal Monitoring Committee (HMC) are vital in ensuring compliance and fostering trust in halal healthcare products among consumers in the UK. The rising demand for halal certified medicines is driven by increased awareness of the importance of religious adherence in healthcare, alongside growing ethical considerations.
However, market players face challenges such as the complexity of obtaining dual certifications (halal and regulatory) and the limited availability of halal-compliant raw materials. Recent trends point to a shift toward personalized medicine, with consumers seeking tailored healthcare solutions that align with both religious and ethical beliefs.
In France, the halal pharmaceutical industry is regulated by bodies such as AVS and Halal Services France, which provide stringent certification to ensure product authenticity. Consumer preferences are evolving toward products that meet halal requirements and prioritize natural, cruelty-free, and sustainable ingredients.
Despite this potential, manufacturers often encounter obstacles, including navigating France's secular laws and managing the cost of halal certification. An emerging trend is the use of digital platforms to promote halal pharmaceutical products, increasing their accessibility to a broader audience.
Germany's market holds significant potential, driven by its position as a hub for pharmaceutical innovation and its growing Muslim population. Germany's strict pharmaceutical regulations require halal-certified medications to comply with both Shariah law and EU directives, making the market competitive and challenging.
A preference for ethical and transparent supply chains, with a strong focus on quality assurance, primarily fuels consumer demand. Market entrants face challenges such as overcoming skepticism about halal certifications and meeting the rigorous production standards required for success in this space.
SEGMENTATION ANALYSIS
The Europe halal pharmaceuticals market segmentation includes the market by drug type, dosage form, and distribution channel. The dosage form segment is further differentiated into syrups, capsules, tablets, powders, and other dosage forms.
The dosage form segment in Europe's halal pharmaceuticals industry is dominated by tablets, reflecting their widespread acceptance due to convenience, precise dosing, and extended shelf life. Consumers particularly favor tablets for their ease of administration, portability, and minimal risk of contamination compared to liquid formulations.
The growing demand for halal-certified medicines, including tablets, is driven by their integration into therapeutic categories like pain management, antibiotics, and chronic disease medications. This demand aligns with consumer preferences for reliable and compliant healthcare solutions.
Market players have opportunities to innovate with sugar-free, vegan, and sustainably sourced coatings to appeal to health-conscious and environmentally aware consumers. Additionally, advancements in oral disintegrating tablets (ODTs) present further growth potential, especially for pediatric and geriatric populations.
Thus, regulatory alignment with halal standards, combined with a focus on user-friendly formulations, positions the tablet sub-segment for sustained growth in Europe's halal pharmaceutical landscape.
COMPETITIVE INSIGHTS
Some of the top players operating in the Europe halal pharmaceuticals market include Bosch Pharmaceuticals, Novartis, Pfizer, Merck, etc.
Bosch Pharmaceuticals, based in Karachi, Pakistan, is a prominent pharmaceutical company with a broad range of healthcare solutions. The company specializes in high-quality generics, branded medications, and over-the-counter products.
While its primary markets include the Middle East, South Asia, and Africa, Bosch Pharmaceuticals has been expanding its footprint in the European halal pharmaceuticals sector.
The company's halal-certified portfolio includes antibiotics, anti-allergic medications, cardiovascular treatments, and analgesics, all developed in strict adherence to Shariah compliance. Bosch's dedication to innovation and quality has established it as a trusted provider of ethical healthcare solutions worldwide.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. THE UNITED KINGDOM DOMINATES EUROPE IN HALAL OTC MEDICINE DEMAND
2.5.2. MANUFACTURERS ARE ALIGNING WITH HALAL STANDARDS FOR MENA EXPORTS
2.5.3. INCREASING CONSUMER PREFERENCE FOR ETHICAL AND CLEAN-LABEL PRODUCTS
2.5.4. GROWING FOCUS ON BIOLOGICS AND BIOSIMILARS IN HALAL FORMULATIONS IS EXPANDING
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING MUSLIM POPULATION IS DRIVING DEMAND FOR SHARIA-COMPLIANT HEALTHCARE PRODUCTS
3.1.2. RISING AWARENESS ABOUT HALAL CERTIFICATION AMONG CONSUMERS
3.1.3. EXPANSION OF HALAL PHARMACEUTICAL MANUFACTURING IN NON-MUSLIM-MAJORITY COUNTRIES
3.2. KEY RESTRAINTS
3.2.1. HIGH COSTS ASSOCIATED WITH HALAL CERTIFICATION AND COMPLIANCE
3.2.2. LIMITED AVAILABILITY OF HALAL-CERTIFIED RAW MATERIALS
3.2.3. REGULATORY INCONSISTENCIES ACROSS DIFFERENT REGIONS ARE AFFECTING MARKET ENTRY
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS - HALAL
4.2. KEY MARKET TRENDS
4.2.1. MAINSTREAM PHARMACIES IN FRANCE AND THE UK ARE ADOPTING HALAL PHARMACEUTICALS
4.2.2. ADOPTION OF ADVANCED TECHNOLOGIES FOR HALAL COMPLIANCE IN DRUG MANUFACTURING PROCESSES
4.2.3. INCREASING R&D INVESTMENTS IN HALAL BIOPHARMACEUTICALS
4.2.4. RISING COLLABORATIONS BETWEEN PHARMACEUTICAL COMPANIES AND HALAL CERTIFICATION BODIES
4.3. PORTER'S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RAW MATERIAL SOURCING AND CERTIFICATION
4.7.2. RESEARCH AND DEVELOPMENT OF HALAL FORMULATIONS
4.7.3. HALAL-CERTIFIED MANUFACTURING PROCESSES
4.7.4. QUALITY ASSURANCE AND REGULATORY COMPLIANCE
4.7.5. PACKAGING AND LABELING WITH HALAL STANDARDS
4.7.6. DISTRIBUTION AND SUPPLY CHAIN MANAGEMENT
4.7.7. RETAIL AND CONSUMER OUTREACH
4.8. REGULATORY FRAMEWORK AND COMPLIANCE BODIES
5. MARKET BY DRUG TYPE
5.1. ANALGESICS
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. PAIN MANAGEMENT DRUGS
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
5.3. ANTI-INFLAMMATORY DRUGS
5.3.1. MARKET FORECAST FIGURE
5.3.2. SEGMENT ANALYSIS
5.4. RESPIRATORY DRUGS
5.4.1. MARKET FORECAST FIGURE
5.4.2. SEGMENT ANALYSIS
5.5. CARDIOVASCULAR DRUGS
5.5.1. MARKET FORECAST FIGURE
5.5.2. SEGMENT ANALYSIS
5.6. VACCINES
5.6.1. MARKET FORECAST FIGURE
5.6.2. SEGMENT ANALYSIS
5.7. OTHER DRUG TYPES
5.7.1. MARKET FORECAST FIGURE
5.7.2. SEGMENT ANALYSIS
6. MARKET BY DOSAGE FORM
6.1. SYRUPS
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. CAPSULES
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
6.3. TABLETS
6.3.1. MARKET FORECAST FIGURE
6.3.2. SEGMENT ANALYSIS
6.4. POWDERS
6.4.1. MARKET FORECAST FIGURE
6.4.2. SEGMENT ANALYSIS
6.5. OTHER DOSAGE FORMS
6.5.1. MARKET FORECAST FIGURE
6.5.2. SEGMENT ANALYSIS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. PHARMACIES
7.1.1. MARKET FORECAST FIGURE
7.1.2. SEGMENT ANALYSIS
7.2. HOSPITALS
7.2.1. MARKET FORECAST FIGURE
7.2.2. SEGMENT ANALYSIS
7.3. OTHER DISTRIBUTION CHANNELS
7.3.1. MARKET FORECAST FIGURE
7.3.2. SEGMENT ANALYSIS
8. GEOGRAPHICAL ANALYSIS
8.1. EUROPE
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. COUNTRY ANALYSIS
8.1.2.1. UNITED KINGDOM
8.1.2.1.1. UNITED KINGDOM HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.2. GERMANY
8.1.2.2.1. GERMANY HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.3. FRANCE
8.1.2.3.1. FRANCE HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.4. SPAIN
8.1.2.4.1. SPAIN HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.5. ITALY
8.1.2.5.1. ITALY HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.6. NETHERLANDS
8.1.2.6.1. NETHERLANDS HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.7. BELGIUM
8.1.2.7.1. BELGIUM HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
8.1.2.8. REST OF EUROPE
8.1.2.8.1. REST OF EUROPE HALAL PHARMACEUTICALS MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ABBVIE
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. BOSCH PHARMACEUTICALS
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. CCM PHARMACEUTICALS SDN BHD
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. CHEMICAL COMPANY OF MALAYSIA BHD
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. EMBIL PHARMACEUTICALS CO LTD
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCT LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. HOVID
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCT LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. MERCK
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. PRODUCT LIST
9.2.7.3. STRENGTHS & CHALLENGES
9.2.8. NOOR VITAMINS
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. PRODUCT LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. NOVARTIS
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. PRODUCT LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. NUTRAMEDICAL INCORPORATED
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. PRODUCT LIST
9.2.10.3. STRENGTHS & CHALLENGES
9.2.11. PFIZER
9.2.11.1. COMPANY OVERVIEW
9.2.11.2. PRODUCT LIST
9.2.11.3. STRENGTHS & CHALLENGES
9.2.12. PHARMANIAGA BHD
9.2.12.1. COMPANY OVERVIEW
9.2.12.2. PRODUCT LIST
9.2.12.3. STRENGTHS & CHALLENGES
9.2.13. ROSEMONT PHARMACEUTICALS
9.2.13.1. COMPANY OVERVIEW
9.2.13.2. PRODUCT LIST
9.2.13.3. STRENGTHS & CHALLENGES
9.2.14. SANOFI
9.2.14.1. COMPANY OVERVIEW
9.2.14.2. PRODUCT LIST
9.2.14.3. STRENGTHS & CHALLENGES
9.2.15. SIMPOR PHARMA SENDIRIAN BERHAD
9.2.15.1. COMPANY OVERVIEW
9.2.15.2. PRODUCT LIST
9.2.15.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - HALAL PHARMACEUTICALS
TABLE 2: REGULATORY FRAMEWORK AND COMPLIANCE BODIES
TABLE 3: EUROPE HALAL PHARMACEUTICALS MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
TABLE 4: EUROPE HALAL PHARMACEUTICALS MARKET, BY DRUG TYPE, FORECAST YEARS, 2025-2032 (IN $ MILLION)
TABLE 5: EUROPE HALAL PHARMACEUTICALS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
TABLE 6: EUROPE HALAL PHARMACEUTICALS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2025-2032 (IN $ MILLION)
TABLE 7: EUROPE HALAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
TABLE 8: EUROPE HALAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2025-2032 (IN $ MILLION)
TABLE 9: EUROPE HALAL PHARMACEUTICALS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
TABLE 10: EUROPE HALAL PHARMACEUTICALS MARKET, BY COUNTRY, FORECAST YEARS, 2025-2032 (IN $ MILLION)
TABLE 11: LIST OF MERGERS & ACQUISITIONS
TABLE 12: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 13: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 14: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: MAJOR MARKET FINDINGS
FIGURE 2: MARKET DYNAMICS
FIGURE 3: KEY MARKET TRENDS
FIGURE 4: PORTER'S FIVE FORCES ANALYSIS
FIGURE 5: GROWTH PROSPECT MAPPING
FIGURE 6: MARKET MATURITY ANALYSIS
FIGURE 7: MARKET CONCENTRATION ANALYSIS
FIGURE 8: VALUE CHAIN ANALYSIS
FIGURE 9: EUROPE HALAL PHARMACEUTICALS MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2024
FIGURE 10: EUROPE HALAL PHARMACEUTICALS MARKET, BY ANALGESICS, 2025-2032 (IN $ MILLION)
FIGURE 11: EUROPE HALAL PHARMACEUTICALS MARKET, BY PAIN MANAGEMENT DRUGS, 2025-2032 (IN $ MILLION)
FIGURE 12: EUROPE HALAL PHARMACEUTICALS MARKET, BY ANTI-INFLAMMATORY DRUGS, 2025-2032 (IN $ MILLION)
FIGURE 13: EUROPE HALAL PHARMACEUTICALS MARKET, BY RESPIRATORY DRUGS, 2025-2032 (IN $ MILLION)
FIGURE 14: EUROPE HALAL PHARMACEUTICALS MARKET, BY CARDIOVASCULAR DRUGS, 2025-2032 (IN $ MILLION)
FIGURE 15: EUROPE HALAL PHARMACEUTICALS MARKET, BY VACCINES, 2025-2032 (IN $ MILLION)
FIGURE 16: EUROPE HALAL PHARMACEUTICALS MARKET, BY OTHER DRUG TYPES, 2025-2032 (IN $ MILLION)
FIGURE 17: EUROPE HALAL PHARMACEUTICALS MARKET, GROWTH POTENTIAL, BY DOSAGE FORM, IN 2024
FIGURE 18: EUROPE HALAL PHARMACEUTICALS MARKET, BY SYRUPS, 2025-2032 (IN $ MILLION)
FIGURE 19: EUROPE HALAL PHARMACEUTICALS MARKET, BY CAPSULES, 2025-2032 (IN $ MILLION)
FIGURE 20: EUROPE HALAL PHARMACEUTICALS MARKET, BY TABLETS, 2025-2032 (IN $ MILLION)
FIGURE 21: EUROPE HALAL PHARMACEUTICALS MARKET, BY POWDERS, 2025-2032 (IN $ MILLION)
FIGURE 22: EUROPE HALAL PHARMACEUTICALS MARKET, BY OTHER DOSAGE FORMS, 2025-2032 (IN $ MILLION)
FIGURE 23: EUROPE HALAL PHARMACEUTICALS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2024
FIGURE 24: EUROPE HALAL PHARMACEUTICALS MARKET, BY PHARMACIES, 2025-2032 (IN $ MILLION)
FIGURE 25: EUROPE HALAL PHARMACEUTICALS MARKET, BY HOSPITALS, 2025-2032 (IN $ MILLION)
FIGURE 26: EUROPE HALAL PHARMACEUTICALS MARKET, BY OTHER DISTRIBUTION CHANNELS, 2025-2032 (IN $ MILLION)
FIGURE 27: EUROPE HALAL PHARMACEUTICALS MARKET, COUNTRY OUTLOOK, 2024 & 2032 (IN %)
FIGURE 28: UNITED KINGDOM HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 29: GERMANY HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 30: FRANCE HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 31: SPAIN HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 32: ITALY HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 33: NETHERLANDS HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 34: BELGIUM HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
FIGURE 35: REST OF EUROPE HALAL PHARMACEUTICALS MARKET, 2025-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security